Center-Authored Papers

Filters: Author is Antin, Joseph H  [Clear All Filters]
2008
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ.  2008.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(2):197-207. Abstract
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
2009
Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C et al..  2009.  HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(10):1644-52. Abstract
McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, Antin JH, Lee SJ, Ruutu T, Storer BE et al..  2009.  Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.. Nature genetics. 41(12):1341-4. Abstract
Oliansky DM, Antin JH, Bennett JM, Deeg HJ, Engelhardt C, Heptinstall KV, DeLima M, Gore SD, Potts RG, Silverman LR et al..  2009.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(2):137-72. Abstract
Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H et al..  2009.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.. JAMA : the journal of the American Medical Association. 301(22):2349-61. Abstract
Ringdén O, Pavletic SZ, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C et al..  2009.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.. Blood. 113(13):3110-8. Abstract
Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn J-Y, Cervantes F, Copelan E et al..  2009.  Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(11):1475-8. Abstract
2010
Storb R, Antin JH, Cutler C.  2010.  Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(1 Suppl):S18-27. Abstract
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB et al..  2010.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(7):1005-17. Abstract
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
2011
Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers MED, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M et al..  2011.  Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.. Blood. 117(24):6714-20. Abstract
Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R et al..  2011.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network,. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(3):291-9. Abstract
Jacobsohn DA, Arora M, Klein JP, Hassebroek A, Flowers MED, Cutler CS, Urbano-Ispizua A, Bolwell BJ, Antin JH, Boyiadzis M et al..  2011.  Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.. Blood. 118(16):4472-9. Abstract
Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J, Passweg JR, Tolar J, Horowitz MM, Marsh JCW et al..  2011.  Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.. Blood. 118(9):2618-21. Abstract
Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P et al..  2011.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.. The lancet oncology. Abstract
2012
Armand P, Kim HT, Zhang M-J, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM et al..  2012.  Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(2):280-288. Abstract
Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang M-J et al..  2012.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.. Blood. 119(1):296-307. Abstract
Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID et al..  2012.  Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(7):1007-11. Abstract
Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C et al..  2012.  Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ et al..  2012.  A disease risk index for patients undergoing allogeneic stem cell transplantation.. Blood. 120(4):905-13. Abstract
2013
Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, Bodhi P, Davis J, Davies SM, Deconinck E et al..  2013.  Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(8):1238-43. Abstract
Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong C-H, Wang H, Chin A et al..  2013.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.. The New England journal of medicine. 369(6):529-39. Abstract
2014
Kim S-Y, Le Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, Carreras J, Kurtzberg J, Nakamura R, Eapen M et al..  2014.  Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.. Haematologica. 99(12):1868-75. Abstract
McClune BL, Woo Ahn K, Wang H-L, Antin JH, Artz AS, Cahn J-Y, Deol A, Freytes CO, Hamadani M, Holmberg LA et al..  2014.  Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(7):960-8. Abstract